Mevaseret Zion, Israel

Dorit Michaeli

This inventor holds 1 USPTO granted patent. Top assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.. Active years: 2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dorit Michaeli. Retrieved from https://idiyas.com/inventor/dorit-michaeli

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Dorit Michaeli: Innovator in Cancer Treatment

Introduction

Dorit Michaeli is a notable inventor based in Mevaseret Zion, Israel. She has made significant contributions to the field of cancer treatment through her innovative research and development. Her work focuses on peptides derived from the human NAF-1 protein, which have potential therapeutic applications.

Latest Patents

Dorit Michaeli holds a patent for "NAF-1 derived peptides and uses thereof." This invention provides peptides that comprise a sequence derived from the human NAF-1 protein, as well as analogs of this sequence or retro-inverso sequences of the peptides or analogs. The conjugates of these peptides are also included in the patent. The peptides and their conjugates are particularly useful in treating cancer, especially in cases where the expression of NAF-1 is enhanced. She has 1 patent to her name.

Career Highlights

Dorit Michaeli is associated with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. This organization plays a crucial role in the commercialization of academic research and innovations. Her work at Yissum has allowed her to contribute to advancements in medical science, particularly in oncology.

Collaborations

Dorit Michaeli has collaborated with several esteemed colleagues, including Rachel Nechushtai and Anat Iosub-Amir. These collaborations have fostered a productive research environment, leading to significant advancements in their respective fields.

Conclusion

Dorit Michaeli's innovative work in developing NAF-1 derived peptides showcases her commitment to advancing cancer treatment. Her contributions are paving the way for new therapeutic options in oncology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…